{"id":"NCT02549339","sponsor":"LEO Pharma","briefTitle":"Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up","officialTitle":"Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-11-13","primaryCompletion":"2016-08-05","completion":"2017-08-10","firstPosted":"2015-09-15","resultsPosted":"2018-11-14","lastUpdate":"2025-03-10"},"enrollment":383,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Actinic Keratosis"],"interventions":[{"type":"DRUG","name":"LEO 43204 gel","otherNames":[]},{"type":"DRUG","name":"Vehicle gel","otherNames":[]}],"arms":[{"label":"LEO 43204 gel","type":"EXPERIMENTAL"},{"label":"Vehicle gel","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of the trial is to compare the short term efficacy of LEO 43204 gel with vehicle gel in AK on face or chest when applied topically once daily for 3 consecutive days as field treatment","primaryOutcome":{"measure":"Complete Clearance of Actinic Keratosis (AK)","timeFrame":"At Week 8","effectByArm":[{"arm":"LEO 43204 0.018% Gel","deltaMin":20.4,"sd":null},{"arm":"Vehicle Gel","deltaMin":2.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["https://www.leopharmatrials.com/en"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":202},"commonTop":["Application site pain","Application site pruritus","Basal cell carcinoma","Bowen's disease","Squamous cell carcinoma of skin"]}}